NasdaqGM:ATRC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. More Details


Snowflake Analysis

Adequate balance sheet with concerning outlook.


Similar Companies

Share Price & News

How has AtriCure's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ATRC has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.6%

ATRC

1.1%

US Medical Equipment

1.0%

US Market


1 Year Return

56.2%

ATRC

15.4%

US Medical Equipment

13.6%

US Market

Return vs Industry: ATRC exceeded the US Medical Equipment industry which returned 15.4% over the past year.

Return vs Market: ATRC exceeded the US Market which returned 13.6% over the past year.


Shareholder returns

ATRCIndustryMarket
7 Day-1.6%1.1%1.0%
30 Day-2.3%1.5%-0.4%
90 Day-10.3%12.0%8.9%
1 Year56.2%56.2%16.4%15.4%16.2%13.6%
3 Year81.9%81.9%73.3%68.8%40.2%30.8%
5 Year99.1%99.1%149.6%130.6%89.6%68.2%

Price Volatility Vs. Market

How volatile is AtriCure's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AtriCure undervalued compared to its fair value and its price relative to the market?

4.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: ATRC ($39.99) is trading above our estimate of fair value ($12.17)

Significantly Below Fair Value: ATRC is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ATRC is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: ATRC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATRC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATRC is overvalued based on its PB Ratio (4.3x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is AtriCure forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

33.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATRC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATRC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATRC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ATRC's revenue (19.4% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: ATRC's revenue (19.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ATRC is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has AtriCure performed over the past 5 years?

-4.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATRC is currently unprofitable.

Growing Profit Margin: ATRC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ATRC is unprofitable, and losses have increased over the past 5 years at a rate of 4.7% per year.

Accelerating Growth: Unable to compare ATRC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATRC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: ATRC has a negative Return on Equity (-12.02%), as it is currently unprofitable.


Next Steps

Financial Health

How is AtriCure's financial position?


Financial Position Analysis

Short Term Liabilities: ATRC's short term assets ($292.0M) exceed its short term liabilities ($38.1M).

Long Term Liabilities: ATRC's short term assets ($292.0M) exceed its long term liabilities ($249.3M).


Debt to Equity History and Analysis

Debt Level: ATRC's debt to equity ratio (14.4%) is considered satisfactory.

Reducing Debt: ATRC's debt to equity ratio has increased from 7% to 14.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATRC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ATRC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is AtriCure current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ATRC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATRC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATRC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATRC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATRC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Mike Carrel (49 yo)

7.83yrs

Tenure

US$5,829,775

Compensation

Mr. Michael H. Carrel, also known as Mike, serves as the Chief Executive Officer and President of AtriCure, Inc. at Endoscopic Technologies, Inc. since November 2012. Mr. Carrel has been Director since Feb ...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD5.83M) is about average for companies of similar size in the US market ($USD4.56M).

Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Carrel
CEO, President & Director7.83yrsUS$5.83m1.12%
$ 20.2m
Douglas Seith
Chief Operating Officer5.67yrsUS$2.07m0.36%
$ 6.5m
Salvatore Privitera
Chief Technical Officer3.17yrsUS$1.29m0.18%
$ 3.3m
Justin Noznesky
Senior Vice President of Marketing & Business Development4.5yrsUS$1.28m0.11%
$ 2.0m
M. Wade
0.083yrUS$1.68m0.31%
$ 5.6m
Angela Wirick
Chief Financial Officer0.083yrno data0.18%
$ 3.3m
Vinayak Doraiswamy
Senior Vice President of Clinical3.5yrsno datano data
Karl Dahlquist
Chief Legal Officerno datano datano data
Tonya Austin
Senior Vice President of Human Resourcesno datano datano data
Valerie Storch-Willhaus
Senior Director of Corporate Marketing & Communicationsno datano datano data
Theodore Polin
Corporate Secretaryno datano datano data

3.5yrs

Average Tenure

49yo

Average Age

Experienced Management: ATRC's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Carrel
CEO, President & Director7.83yrsUS$5.83m1.12%
$ 20.2m
Sven Wehrwein
Independent Director3.83yrsUS$202.48k0.039%
$ 707.2k
B. Johnson
Independent Director3.5yrsUS$199.98k0.063%
$ 1.1m
Mark Collar
Independent Director12.58yrsUS$192.48k0.19%
$ 3.5m
Mark Lanning
Independent Director14.58yrsUS$199.98k0.30%
$ 5.3m
Scott Drake
Independent Chairman of the Board2.33yrsUS$229.98k0.064%
$ 1.1m
Robert White
Independent Director7.5yrsUS$197.48k0.046%
$ 819.2k
Daniel Florin
Independent Director0.75yrUS$178.80k0.019%
$ 334.0k
Karen Prange
Independent Director0.75yrUS$178.80k0.019%
$ 334.0k
Regina Groves
Independent Director3.5yrsUS$197.48k0.049%
$ 872.2k

3.7yrs

Average Tenure

60yo

Average Age

Experienced Board: ATRC's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ATRC insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.8%.


Top Shareholders

Company Information

AtriCure, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AtriCure, Inc.
  • Ticker: ATRC
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$1.797b
  • Shares outstanding: 44.93m
  • Website: https://www.atricure.com

Number of Employees


Location

  • AtriCure, Inc.
  • 7555 Innovation Way
  • Mason
  • Ohio
  • 45040
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATRCNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDAug 2005
A5IDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2005

Biography

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Syn ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/19 06:20
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.